ViroPharma stock surges on Vancocin price hike

ViroPharma's stock surged yesterday after the company announced its third double-digit price hike on Vancocin since it acquired the antibiotic last December. A 20-unit package of Vancocin will now cost $242.10, up from $195.76. Wall Street loves higher prices for drugs and bid up ViroPharma stock by more than 30 percent. ViroPharma paid Eli Lilly $116 million plus royalties for the drug.

- read this AP report for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.